Compare OTEX & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OTEX | PCVX |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 7.0B |
| IPO Year | 1998 | 2020 |
| Metric | OTEX | PCVX |
|---|---|---|
| Price | $23.07 | $59.23 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $36.10 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 1.2M | 927.4K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.92% | N/A |
| EPS Growth | ★ 56.36 | N/A |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $2,815,241,000.00 | N/A |
| Revenue This Year | $2.82 | N/A |
| Revenue Next Year | $1.04 | N/A |
| P/E Ratio | $8.78 | ★ N/A |
| Revenue Growth | ★ 22.88 | N/A |
| 52 Week Low | $19.78 | $30.81 |
| 52 Week High | $39.90 | $65.00 |
| Indicator | OTEX | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 37.87 | 47.74 |
| Support Level | $21.61 | $58.51 |
| Resistance Level | $23.71 | $63.39 |
| Average True Range (ATR) | 0.66 | 2.10 |
| MACD | -0.27 | -0.39 |
| Stochastic Oscillator | 4.63 | 10.69 |
Open Text Corp provides data management for enterprise AI, offering a secure data foundation and trusted context for credible AI outcomes across private, public, and sovereign cloud, managed cloud services, API, and on-premises environments. The Company also provides cybersecurity solutions to protect sensitive data, applications and systems across complex hybrid environments, including identity and access management, threat detection and response, data protection and application security. It serves private, public, and regulated sectors, including retail, financial services, government, manufacturing, healthcare, energy, and logistics, with clients. Geographically, it derives maximum revenue from the Americas.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.